Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on adolescent vaping

LIVE: Wednesday 29th January, 18:00-19:30 CET

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in:

Open Access 28-09-2024 | Colorectal Cancer | REVIEW

Functional links between the microbiome and the molecular pathways of colorectal carcinogenesis

Authors: Jessica Permain, Barry Hock, Timothy Eglinton, Rachel Purcell

Published in: Cancer and Metastasis Reviews | Issue 4/2024

Login to get access

Abstract

Colorectal cancer (CRC) is a common cancer, with a concerning rise in early-onset CRC cases, signalling a shift in disease epidemiology. Whilst our understanding of the molecular underpinnings of CRC has expanded, the complexities underlying its initiation remain elusive, with emerging evidence implicating the microbiome in CRC pathogenesis. This review synthesizes current knowledge on the intricate interplay between the microbiome, tumour microenvironment (TME), and molecular pathways driving CRC carcinogenesis. Recent studies have reported how the microbiome may modulate the TME and tumour immune responses, consequently influencing cancer progression, and whilst specific bacteria have been linked with CRC, the underlying mechanisms remains poorly understood. By elucidating the functional links between microbial landscapes and carcinogenesis pathways, this review offers insights into how bacteria orchestrate diverse pathways of CRC development, shedding light on potential therapeutic targets and personalized intervention strategies.
Literature
1.
Arnold, M., Sierra, M. S., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2017). Global patterns and trends in colorectal cancer incidence and mortality. Gut, 66(4), 683–691.PubMedCrossRef
2.
3.
Sinicrope, F. A. (2022). Increasing incidence of early-onset colorectal cancer. New England Journal of Medicine, 386(16), 1547–1558.PubMedCrossRef
4.
Flemer, B., Lynch, D. B., Brown, J. M., Jeffery, I. B., Ryan, F. J., Claesson, M. J., . . . O'Toole, P. W. (2017). Tumour-associated and non-tumour-associated microbiota in colorectal cancer. Gut, 66(4), 633–643.
5.
Yu, T., Guo, F., Yu, Y., Sun, T., Ma, D., Han, J., . . . Nagarsheth, N. (2017). Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell, 170(3), 548-563. e516.
6.
Morley-Bunker, A., Walker, L., Currie, M., Pearson, J., & Eglinton, T. (2016). Translating colorectal cancer genetics into clinically useful biomarkers. Colorectal Disease, 18(8), 749–762.PubMedCrossRef
7.
Pino, M. S., & Chung, D. C. (2010). The chromosomal instability pathway in colon cancer. Gastroenterology, 138(6), 2059–2072.PubMedCrossRef
8.
Nguyen, L. H., Goel, A., & Chung, D. C. (2020). Pathways of colorectal carcinogenesis. Gastroenterology, 158(2), 291–302.PubMedCrossRef
9.
Conlin, A., Smith, G., Carey, F. A., Wolf, C. R., & Steele, R. J. (2005). The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut, 54(9), 1283–1286.PubMedPubMedCentralCrossRef
10.
Lemieux, E., Cagnol, S., Beaudry, K., Carrier, J., & Rivard, N. (2015). Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer. Oncogene, 34(38), 4914–4927.PubMedCrossRef
11.
Rennoll, S., & Yochum, G. (2015). Regulation of MYC gene expression by aberrant Wnt/β-catenin signaling in colorectal cancer. World Journal of Biological Chemistry, 6(4), 290.PubMedPubMedCentralCrossRef
12.
Phipps, A. I., Limburg, P. J., Baron, J. A., Burnett-Hartman, A. N., Weisenberger, D. J., Laird, P. W., . . . Potter, J. D. (2015). Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology, 148(1), 77-87. e72.
13.
Kim, C. G., Ahn, J. B., Jung, M., Beom, S. H., Kim, C., Kim, J. H., . . . Kim, N. K. (2016). Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers. British Journal of Cancer, 115(1), 25-33.
14.
Siegel, R. L., Wagle, N. S., Cercek, A., Smith, R. A., & Jemal, A. (2023). Colorectal cancer statistics, 2023. CA: a Cancer Journal for Clinicians, 73(3), 233–254.PubMed
15.
Leggett, B., & Whitehall, V. (2010). Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology, 138(6), 2088–2100.PubMedCrossRef
16.
Mezzapesa, M., Losurdo, G., Celiberto, F., Rizzi, S., d’Amati, A., Piscitelli, D., . . . Di Leo, A. (2022). Serrated colorectal lesions: an up-to-date review from histological pattern to molecular pathogenesis. International Journal of Molecular Sciences, 23(8), 4461
17.
Gupta, R., Sinha, S., & Paul, R. N. (2018). The impact of microsatellite stability status in colorectal cancer. Current Problems in Cancer, 42(6), 548–559.PubMedCrossRef
18.
Yamagishi, H., Kuroda, H., Imai, Y., & Hiraishi, H. (2016). Molecular pathogenesis of sporadic colorectal cancers. Chinese Journal of Cancer, 35, 1–8.CrossRef
19.
Hawkins, N., Norrie, M., Cheong, K., Mokany, E., Ku, S. L., Meagher, A., . . . Ward, R. (2002). CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology, 122(5), 1376-1387.
20.
Yamane, L., Scapulatempo-Neto, C., Reis, R. M., & Guimarães, D. P. (2014). Serrated pathway in colorectal carcinogenesis. World Journal of Gastroenterology: WJG, 20(10), 2634.PubMedPubMedCentralCrossRef
21.
Fu, X., & Zhang, X. (2014). BRAF mutation as a potential marker to identify the proximal colon serrated polyps with malignant potential. International Journal of Clinical and Experimental Pathology, 7(11), 7319.PubMedPubMedCentral
22.
Borowsky, J., Dumenil, T., Bettington, M., Pearson, S.-A., Bond, C., Fennell, L., . . . Brown, I. (2018). The role of APC in WNT pathway activation in serrated neoplasia. Modern Pathology, 31(3), 495-504.
23.
Guinney, J., Dienstmann, R., Wang, X., De Reynies, A., Schlicker, A., Soneson, C., . . . Angelino, P. (2015). The consensus molecular subtypes of colorectal cancer. Nature Medicine, 21(11), 1350-1356
24.
Purcell, R. V., Visnovska, M., Biggs, P. J., Schmeier, S., & Frizelle, F. A. (2017). Distinct gut microbiome patterns associate with consensus molecular subtypes of colorectal cancer. Scientific Reports, 7(1), 1–12.CrossRef
25.
Flanagan, L., Schmid, J., Ebert, M., Soucek, P., Kunicka, T., Liska, V., . . . Tommasino, M. (2014). Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. European Journal of Clinical Microbiology & Infectious Diseases, 33(8), 1381-1390.
26.
Mima, K., Nishihara, R., Qian, Z. R., Cao, Y., Sukawa, Y., Nowak, J. A., . . . Song, M. (2016). Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut, 65(12), 1973-1980.
27.
Kostic, A. D., Chun, E., Robertson, L., Glickman, J. N., Gallini, C. A., Michaud, M., . . . Hold, G. L. (2013). Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host & Microbe, 14(2), 207-215.
28.
Mima, K., Sukawa, Y., Nishihara, R., Qian, Z. R., Yamauchi, M., Inamura, K., . . . Nosho, K. (2015). Fusobacterium nucleatum and T cells in colorectal carcinoma. JAMA Oncology, 1(5), 653-661.
29.
Stintzing, S., Wirapati, P., Lenz, H.-J., Neureiter, D., Von Weikersthal, L. F., Decker, T., . . . Heintges, T. (2019). Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial. Annals of Oncology, 30(11), 1796-1803.
30.
31.
Sulit, A., Daigneault, M., Allen-Vercoe, E., Silander, O., Hock, B., McKenzie, J., . . . Purcell, R. (2023). Bacterial lipopolysaccharide modulates immune response in the colorectal tumor microenvironment. npj Biofilms and Microbiomes, 9(1), 59.
32.
Zamani, S., Taslimi, R., Sarabi, A., Jasemi, S., Sechi, L. A., & Feizabadi, M. M. (2020). Enterotoxigenic Bacteroides fragilis: A possible etiological candidate for bacterially-induced colorectal precancerous and cancerous lesions. Frontiers in Cellular and Infection Microbiology, 9, 449.PubMedPubMedCentralCrossRef
33.
Khodaverdi, N., Zeighami, H., Jalilvand, A., Haghi, F., & Hesami, N. (2021). High frequency of enterotoxigenic Bacteroides fragilis and Enterococcus faecalis in the paraffin-embedded tissues of Iranian colorectal cancer patients. BMC Cancer, 21(1), 1–7.CrossRef
34.
Purcell, R. V., Pearson, J., Aitchison, A., Dixon, L., Frizelle, F. A., & Keenan, J. I. (2017). Colonization with enterotoxigenic Bacteroides fragilis is associated with early-stage colorectal neoplasia. PLoS ONE, 12(2), e0171602.PubMedPubMedCentralCrossRef
35.
Purcell, R. V., Permain, J., & Keenan, J. I. (2022). Enterotoxigenic Bacteroides fragilis activates IL-8 expression through Stat3 in colorectal cancer cells. Gut Pathogens, 14(1), 1–7.CrossRef
36.
Li, J., Huang, L., Zhao, H., Yan, Y., & Lu, J. (2020). The role of interleukins in colorectal cancer. International Journal of Biological Sciences, 16(13), 2323.PubMedPubMedCentralCrossRef
37.
Ternes, D., Tsenkova, M., Pozdeev, V. I., Meyers, M., Koncina, E., Atatri, S., . . . Heinken, A. (2022). The gut microbial metabolite formate exacerbates colorectal cancer progression. Nature Metabolism, 4(4), 458-475.
38.
39.
De Rycke, J., & Oswald, E. (2001). Cytolethal distending toxin (CDT): A bacterial weapon to control host cell proliferation? FEMS Microbiology Letters, 203(2), 141–148.PubMedCrossRef
40.
Ge, Z., Feng, Y., Ge, L., Parry, N., Muthupalani, S., & Fox, J. G. (2017). Helicobacter hepaticus cytolethal distending toxin promotes intestinal carcinogenesis in 129Rag2-deficient mice. Cellular Microbiology, 19(7), e12728.CrossRef
41.
Liyanage, N. P., Manthey, K. C., Dassanayake, R. P., Kuszynski, C. A., Oakley, G. G., & Duhamel, G. E. (2010). Helicobacter hepaticus cytolethal distending toxin causes cell death in intestinal epithelial cells via mitochondrial apoptotic pathway. Helicobacter, 15(2), 98–107.PubMedCrossRef
42.
Tremblay, W., Mompart, F., Lopez, E., Quaranta, M., Bergoglio, V., Hashim, S., . . . Trouche, D. (2021). Cytolethal distending toxin promotes replicative stress leading to genetic instability transmitted to daughter cells. Frontiers in Cell and Developmental Biology, 9, 656795.
43.
Guidi, R., Guerra, L., Levi, L., Stenerlöw, B., Fox, J. G., Josenhans, C., . . . Frisan, T. (2013). Chronic exposure to the cytolethal distending toxins of Gram‐negative bacteria promotes genomic instability and altered DNA damage response. Cellular Microbiology, 15(1), 98-113.
44.
He, Z., Gharaibeh, R. Z., Newsome, R. C., Pope, J. L., Dougherty, M. W., Tomkovich, S., . . . Hendrixson, D. R. (2019). Campylobacter jejuni promotes colorectal tumorigenesis through the action of cytolethal distending toxin. Gut, 68(2), 289-300.
45.
46.
Cuevas-Ramos, G., Petit, C. R., Marcq, I., Boury, M., Oswald, E., & Nougayrède, J.-P. (2010). Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells. Proceedings of the National Academy of Sciences, 107(25), 11537–11542.CrossRef
47.
Pleguezuelos-Manzano, C., Puschhof, J., Rosendahl Huber, A., van Hoeck, A., Wood, H. M., Nomburg, J., . . . Stege, P. B. (2020). Mutational signature in colorectal cancer caused by genotoxic pks+ E. coli. Nature, 580(7802), 269–273.
48.
Boleij, A., Hechenbleikner, E. M., Goodwin, A. C., Badani, R., Stein, E. M., Lazarev, M. G., . . . Wick, E. C. (2015). The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients. Clinical Infectious Diseases, 60(2), 208-215.
49.
Choi, V. M. (2015). Characterization of virulence-associated protein processing genes in Bacteroides fragilis. The University of Chicago.
50.
Goodwin, A. C., Shields, C. E. D., Wu, S., Huso, D. L., Wu, X., Murray-Stewart, T. R., . . . Sears, C. L. (2011). Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis. Proceedings of the National Academy of Sciences, 108(37), 15354-15359.
51.
Wu, S., Morin, P. J., Maouyo, D., & Sears, C. L. (2003). Bacteroides fragilis enterotoxin induces c-Myc expression and cellular proliferation. Gastroenterology, 124(2), 392–400.PubMedCrossRef
52.
Zhao, H., Ming, T., Tang, S., Ren, S., Yang, H., Liu, M., . . . Xu, H. (2022). Wnt signaling in colorectal cancer: Pathogenic role and therapeutic target. Molecular Cancer, 21(1), 144.
53.
Lee, C.-G., Hwang, S., Gwon, S.-Y., Park, C., Jo, M., Hong, J.-E., & Rhee, K.-J. (2022). Bacteroides fragilis toxin induces intestinal epithelial cell secretion of interleukin-8 by the e-Cadherin/β-Catenin/NF-κB dependent pathway. Biomedicines, 10(4), 827.PubMedPubMedCentralCrossRef
54.
Itoh, Y., Joh, T., Tanida, S., Sasaki, M., Kataoka, H., Itoh, K., . . . Wada, T. (2005). IL-8 promotes cell proliferation and migration through metalloproteinase-cleavage proHB-EGF in human colon carcinoma cells. Cytokine, 29(6), 275-282.
55.
Fousek, K., Horn, L. A., & Palena, C. (2021). Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression. Pharmacology & Therapeutics, 219, 107692.CrossRef
56.
Chen, X., Wang, Y., Xia, H., Wang, Q., Jiang, X., Lin, Z., . . . Hu, M. (2012). Loss of E-cadherin promotes the growth, invasion and drug resistance of colorectal cancer cells and is associated with liver metastasis. Molecular Biology Reports, 39, 6707-6714.
57.
Huang, C.-Y., & Wang, M.-C. (2020). Clostridium perfringens bacteremia associated with colorectal cancer in an elderly woman. The Turkish Journal of Gastroenterology, 31(12), 960.PubMedPubMedCentralCrossRef
58.
Kohya, R., Murai, T., Taguchi, Y., Sawai, K., Takehara, M., Nagahama, M., . . . Ono, Y. (2022). An autopsy case of rapidly aggravated Clostridium perfringens septicemia with colorectal cancer. Case Reports in Infectious Diseases, 2022. https://​doi.​org/​10.​1155/​2022/​1071582
59.
Fujiwara-Tani, R., Fujii, K., Mori, S., Kishi, S., Sasaki, T., Ohmori, H., Nakashima, C., et al. (2020). Role of Clostridium perfringens enterotoxin on YAP activation in colonic sessile serrated adenoma/polyps with dysplasia. International Journal of Molecular Sciences, 21(11), 3840. MDPI AG.PubMedPubMedCentralCrossRef
60.
Fujiwara-Tani, R., Mori, S., Ogata, R., Sasaki, R., Ikemoto, A., Kishi, S., ... & Kuniyasu, H. (2023). Claudin-4: A new molecular target for epithelial cancer therapy. International Journal of Molecular Sciences, 24(6), 5494.
61.
Allali, I., Boukhatem, N., Bouguenouch, L., Hardi, H., Boudouaya, H. A., Cadenas, M. B., ... & Ghazal, H. (2018). Gut microbiome of Moroccan colorectal cancer patients. Medical Microbiology and Immunology, 207, 211-225.
62.
Jahani-Sherafat, S., Azimirad, M., Alebouyeh, M., Amoli, H. A., Hosseini, P., Ghasemian-Safaei, H., & Moghim, S. (2019). The rate and importance of Clostridium difficile in colorectal cancer patients. Gastroenterology and Hepatology From bed to Bench, 12(4), 358.PubMedPubMedCentral
63.
Caroff, M., & Karibian, D. (2003). Structure of bacterial lipopolysaccharides. Carbohydrate Research, 338(23), 2431–2447.PubMedCrossRef
64.
Lu, Y. C., Yeh, W. C., & Ohashi, P. S. (2008). LPS/TLR4 signal transduction pathway. Cytokine, 42(2), 145–151.PubMedCrossRef
65.
Miao, E. A., Andersen-Nissen, E., Warren, S. E., & Aderem, A. (2007). TLR5 and Ipaf: dual sensors of bacterial flagellin in the innate immune system. In Seminars in immunopathology (Vol. 29, pp. 275–288). Springer-Verlag.
66.
67.
Mantovani, A., Romero, P., Palucka, A. K., & Marincola, F. M. (2008). Tumour immunity: Effector response to tumour and role of the microenvironment. The lancet, 371(9614), 771–783.CrossRef
68.
Kostic, A. D., Chun, E., Robertson, L., Glickman, J. N., Gallini, C. A., Michaud, M., ... & Garrett, W. S. (2013). Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host & Microbe, 14(2), 207-215.
69.
Orberg, E. T., Fan, H., Tam, A. J., Dejea, C. M., Shields, C. D., Wu, S., ... & Housseau, F. (2017). The myeloid immune signature of enterotoxigenic Bacteroides fragilis-induced murine colon tumorigenesis. Mucosal Immunology, 10(2), 421-433.
70.
Liu, X., Chen, Y., Zhang, S., & Dong, L. (2021). Gut microbiota-mediated immunomodulation in tumor. Journal of Experimental & Clinical Cancer Research, 40(1), 1–20.CrossRef
71.
Hu, L., Liu, Y., Kong, X., Wu, R., Peng, Q., Zhang, Y., ... & Duan, L. (2021). Fusobacterium nucleatum facilitates M2 macrophage polarization and colorectal carcinoma progression by activating TLR4/NF-κ B/S100A9 cascade. Frontiers in Immunology, 12, 658681.
72.
Batah, J., Kobeissy, H., Bui Pham, P. T., Denève-Larrazet, C., Kuehne, S., Collignon, A., ... & Kansau, I. (2017). Clostridium difficile flagella induce a pro-inflammatory response in intestinal epithelium of mice in cooperation with toxins. Scientific Reports, 7(1), 3256.
73.
Waldner, M. J., Foersch, S., & Neurath, M. F. (2012). Interleukin-6-a key regulator of colorectal cancer development. International Journal of Biological Sciences, 8(9), 1248.PubMedPubMedCentralCrossRef
74.
Tominaga, K., Yoshimoto, T., Torigoe, K., Kurimoto, M., Matsui, K., Hada, T., ... & Nakanishi, K. (2000). IL-12 synergizes with IL-18 or IL-1β for IFN-γ production from human T cells. International Immunology, 12(2), 151-160.
75.
Trinchieri, G. (2003). Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nature Reviews Immunology, 3(2), 133–146.PubMedCrossRef
76.
Oft, M. (2014). IL-10: Master switch from tumor-promoting inflammation to antitumor immunity. Cancer Immunology Research, 2(3), 194–199.PubMedCrossRef
77.
Dai, Z., Coker, O. O., Nakatsu, G., Wu, W. K., Zhao, L., Chen, Z., ... & Yu, J. (2018). Multi-cohort analysis of colorectal cancer metagenome identified altered bacteria across populations and universal bacterial markers. Microbiome, 6(1), 1-12.
78.
Wu, S., Rhee, K. J., Zhang, M., Franco, A., & Sears, C. L. (2007). Bacteroides fragilis toxin stimulates intestinal epithelial cell shedding and γ-secretase-dependent E-cadherin cleavage. Journal of Cell Science, 120(11), 1944–1952.PubMedCrossRef
79.
Page, M. J., Kell, D. B., & Pretorius, E. (2022). The role of lipopolysaccharide-induced cell signalling in chronic inflammation. Chronic Stress, 6, 24705470221076390.PubMedPubMedCentralCrossRef
80.
Parada Venegas, D., De la Fuente, M. K., Landskron, G., González, M. J., Quera, R., Dijkstra, G., ... & Hermoso, M. A. (2019). Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Frontiers in immunology, 277.
81.
Arpaia, N., Campbell, C., Fan, X., Dikiy, S., Van Der Veeken, J., Deroos, P., ... & Rudensky, A. Y. (2013). Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature, 504(7480), 451-455.
82.
Li, C., Jiang, P., Wei, S., Xu, X., & Wang, J. (2020). Regulatory T cells in tumor microenvironment: New mechanisms, potential therapeutic strategies and future prospects. Molecular Cancer, 19, 1–23.PubMedPubMedCentralCrossRef
83.
Keum, N., & Giovannucci, E. (2019). Global burden of colorectal cancer: Emerging trends, risk factors and prevention strategies. Nature reviews Gastroenterology & Hepatology, 16(12), 713–732.CrossRef
84.
Pulendran, B., Kumar, P., Cutler, C. W., Mohamadzadeh, M., Van Dyke, T., & Banchereau, J. (2001). Lipopolysaccharides from distinct pathogens induce different classes of immune responses in vivo. The Journal of Immunology, 167(9), 5067–5076.PubMedCrossRef
85.
Darveau, R. P., Pham, T. T. T., Lemley, K., Reife, R. A., Bainbridge, B. W., Coats, S. R., ... & Hajjar, A. M. (2004). Porphyromonas gingivalis lipopolysaccharide contains multiple lipid A species that functionally interact with both toll-like receptors 2 and 4. Infection and Immunity, 72(9), 5041-5051.
86.
Czajka-Francuz, P., Cisoń-Jurek, S., Czajka, A., Kozaczka, M., Wojnar, J., Chudek, J., & Francuz, T. (2021). Systemic Interleukins’ profile in early and advanced colorectal cancer. International Journal of Molecular Sciences, 23(1), 124.PubMedPubMedCentralCrossRef
87.
Gao, Y., Bi, D., Xie, R., Li, M., Guo, J., Liu, H., ... & Qin, H. (2021). Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer. Signal Transduction and Targeted Therapy, 6(1), 398.
88.
Mager, L. F., Burkhard, R., Pett, N., Cooke, N. C., Brown, K., Ramay, H., ... & McCoy, K. D. (2020). Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science, 369(6510), 1481-1489.
89.
Lopès, A., Billard, E., Casse, A. H., Villéger, R., Veziant, J., Roche, G., ... & Bonnet, M. (2020). Colibactin‐positive Escherichia coli induce a procarcinogenic immune environment leading to immunotherapy resistance in colorectal cancer. International Journal of Cancer, 146(11), 3147-3159.
90.
91.
Mouradov, D., Greenfield, P., Li, S., In, E. J., Storey, C., Sakthianandeswaren, A., ... & Sieber, O. M. (2023). Oncomicrobial community profiling identifies clinicomolecular and prognostic subtypes of colorectal cancer. Gastroenterology, 165(1), 104–120.
92.
Zhang, J., Hoedt, E. C., Liu, Q., Berendsen, E., Teh, J. J., Hamilton, A., ... & Ng, S. C. (2021). Elucidation of Proteus mirabilis as a key bacterium in Crohn’s disease inflammation. Gastroenterology, 160(1), 317-330.
93.
Zhang, H., Luo, Y., Zhao, X., & Liu, X. (2024). Engineering Proteus mirabilis improves antitumor efficacy via enhancing cytotoxic T cell responses. Molecular Therapy Oncology, 32(1), 200770.PubMedPubMedCentralCrossRef
94.
Jiang, S. S., Xie, Y. L., Xiao, X. Y., Kang, Z. R., Lin, X. L., Zhang, L., ... & Fang, J. Y. (2023). Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer. Cell Host & Microbe, 31(5), 781-797.
95.
DeStefano Shields, C. E., White, J. R., Chung, L., Wenzel, A., Hicks, J. L., Tam, A. J., ... & Sears, C. L. (2021). Bacterial-driven inflammation and mutant BRAF expression combine to promote murine colon tumorigenesis that is sensitive to immune checkpoint therapy. Cancer Discovery, 11(7), 1792-1807.
Metadata
Title
Functional links between the microbiome and the molecular pathways of colorectal carcinogenesis
Authors
Jessica Permain
Barry Hock
Timothy Eglinton
Rachel Purcell
Publication date
28-09-2024
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 4/2024
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-024-10215-5

Other articles of this Issue 4/2024

Natural killer cells in neuroblastoma: immunological insights and therapeutic perspectives

Racial disparity in prostate cancer: an outlook in genetic and molecular landscape

Tissue factor pathway inhibitor-2 (TFPI-2)—an underappreciated partaker in cancer and metastasis

Advances in the molecular biology of the solitary fibrous tumor and potential impact on clinical applications

Multiomics approach towards characterization of tumor cell plasticity and its significance in precision and personalized medicine

Peptides for microbe-induced cancers: latest therapeutic strategies and their advanced technologies

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Combining tafasitamab with lenalidomide and rituximab significantly improves progression-free survival for patients with relapsed or refractory follicular lymphoma.

Featuring the official presentation video

Read more

Transplantation can be omitted for certain MCL patients

Add-on blinatumomab improves DFS in children with ALL

Promising response to loncastuximab tesirine in lymphoma

» View more highlights on the ASH 2024 hub page

SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now
Image Credits